Share on StockTwits

Celgene (NASDAQ:CELG) is set to post its Q214 quarterly earnings results on Thursday, July 24th. Analysts expect Celgene to post earnings of $0.89 per share and revenue of $1.85 billion for the quarter.

Celgene (NASDAQ:CELG) opened at 86.6576 on Wednesday. Celgene has a one year low of $65.76 and a one year high of $90.50. The stock’s 50-day moving average is $84.33 and its 200-day moving average is $78.58. The company has a market cap of $69.398 billion and a P/E ratio of 54.30.

A number of analysts have recently weighed in on CELG shares. Analysts at Morgan Stanley reiterated an “equal weight” rating on shares of Celgene in a research note on Wednesday, July 16th. They now have a $75.00 price target on the stock. On a related note, analysts at Deutsche Bank reiterated a “buy” rating on shares of Celgene in a research note on Wednesday, July 9th. They now have a $95.00 price target on the stock, down previously from $190.00. Finally, analysts at Nomura cut their price target on shares of Celgene from $252.00 to $126.00 in a research note on Monday, June 30th. They now have a “buy” rating on the stock. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and fifteen have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $99.19.

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.